Evidence map›Paper›PMID 42789184›Full record

ArticleIndian journal of pediatrics2026

Immune Reconstitution in Pediatric Patients Post Autologous Stem Cell Transplantation.

Nupur Bathwar, Satyendra Batra, Arjun Kurup, Jagdish Prasad Meena, Rakesh Kumar Deepak, Pranay Tanwar, Deepam Pushpam, Poonam Coshic, Sujata Mohanty, Sameer Bakhshi and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Indian journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nupur BathwarDepartment of Pediatrics, All India Institute of Medical Sciences, New Delhi, 110029, India.
Satyendra BatraDepartment of Pediatrics, All India Institute of Medical Sciences, New Delhi, 110029, India.
Arjun KurupDepartment of Pediatrics, All India Institute of Medical Sciences, New Delhi, 110029, India.
Jagdish Prasad MeenaDepartment of Pediatrics, All India Institute of Medical Sciences, New Delhi, 110029, India.
Rakesh Kumar Deepak *Department of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi, 110029, India.
Pranay TanwarDivision of Laboratory Oncology, Dr. BRA- IRCH, All India Institute of Medical Sciences, New Delhi, 110029, India.
Deepam PushpamDepartment of Medical Oncology, Dr. BRA- IRCH, All India Institute of Medical Sciences, New Delhi, 110029, India.
Poonam CoshicDepartment of Transfusion Medicine, All India Institute of Medical Sciences, New Delhi, 110029, India.
Sujata MohantyDepartment of Stem Cell Facility, All India Institute of Medical Sciences, New Delhi, 110029, India.
Sameer BakhshiDepartment of Medical Oncology, Dr. BRA- IRCH, All India Institute of Medical Sciences, New Delhi, 110029, India.
Rachna SethDepartment of Pediatrics, All India Institute of Medical Sciences, New Delhi, 110029, India.
Aditya Kumar Gupta *Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, 110029, India. adivick@gmail.com.ORCID http://orcid.org/0000-0002-3730-8944

Funding

Indian Journal of Pediatrics PG thesis grant 2024
6 · The paper itself

Abstract

objectivesTo determine the prevalence of hypogammaglobulinemia at three months post-ASCT and characterize humoral and cellular immune reconstitution kinetics.

methodsTwelve pediatric patients (median age 10 y) undergoing ASCT for high-risk neuroblastoma (n = 4) or relapsed / refractory Hodgkin lymphoma (n = 8) at AIIMS New Delhi (February 2024-November 2025) were prospectively followed. Serial immunoglobulin levels and lymphocyte subsets were measured at baseline and on days +15, +30, +90, +180. Linear mixed-effects models analyzed trajectories on percentages and absolute counts.

resultsMedian IgG at day +90 was 1070 mg/dL (IQR 901-1244). Hypogammaglobulinemia (IgG <500 mg/dL) occurred in 2 of 12 patients (16.7%; 95% CI: 2.1-48.4); both had received rituximab pre-transplant. None of the nine rituximab-naïve patients developed hypogammaglobulinemia. IgM showed a non-significant upward trend at day +90 (p = 0.054), reaching significance at day +180 (p <0.05). Absolute-count analysis demonstrated CD8+ expansion at day +30 (Δ = +652 cells/µL; p = 0.001), profound B-cell depletion at days +15 and +30 (both p <0.01), and a CD4+ deficit at day +90 (Δ = -198 cells/µL; p = 0.017). NK-cell counts remained stable.

conclusionsPediatric ASCT recipients demonstrated predictable immune recovery; hypogammaglobulinemia at three months was confined to rituximab-exposed patients, supporting risk-stratified post-transplant immunoglobulin surveillance and revaccination.

Indexed as

Autologous hematopoietic stem cell transplantationHodgkin lymphomaHypogammaglobulinemiaImmune reconstitutionLymphocyte subsetsNeuroblastomaPediatricsResource-limited settingsRituximab

Identifiers

PMID42789184

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.